Filing Flows

Filing Flows › BioMarin Pharmaceutical (BMRN) › Next earnings date

BioMarin Pharmaceutical (BMRN) earnings: beat the estimate

BioMarin Pharmaceutical (BMRN) reported on Nov 2, 2026 and beat the EPS estimate: $0.23 against −$0.11 (+304.8%). Revenue was $1.0B for Q3 2026, +32% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result+304.8% vs estimate
Beat rate40%

The last report

BioMarin Pharmaceutical reported revenue of $1.0B for the third quarter 2026 (+32% Y/Y), net loss $123M: Net product revenues $1.0B, Royalty and other revenues $11.6M. How it makes money → · Every quarter →

BioMarin Pharmaceutical: EPS against the estimate, last 5 reportsBioMarin Pharmaceutical: EPS against the estimate, last 5 reportsEstimateReported$0.34$0.12Oct 25$0.42−$0.24Feb 26$0.91$0.76May 26$0.95$1.20Aug 26−$0.11$0.23Nov 26
Latest (Nov 26): Estimate −$0.11, Reported $0.23.
BMRN: the stock's move on each reportBMRN: the stock's move on each reportAug 6, 2026+6.5%May 4, 2026-1.5%Feb 23, 2026-2.3%Oct 27, 2025-1.8%

BioMarin Pharmaceutical's latest quarter

BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.

Questions

Did BioMarin Pharmaceutical beat earnings?

BioMarin Pharmaceutical (BMRN) reported on Nov 2, 2026 and beat the EPS estimate: $0.23 against −$0.11 (+304.8%).

When does BMRN report earnings?

The next date is not set yet.

Does BioMarin Pharmaceutical usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.